Medoclazide

Gliclazide, the active ingredient in Medoclazide, is a second‑generation sulfonylurea presented as an oral tablet for oral use. It lowers blood glucose by stimulating insulin release and is indicated for the management of type 2 diabetes mellitus in adult patients. It is marketed in the European Union and is available under prescription.

GNH USA supplies Medoclazide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Gliclazide is a sulfonylurea oral hypoglycemic agent used in the management of disorders related to impaired glucose regulation.

- Type 2 diabetes mellitus: improves glycemic control by increasing insulin secretion. - Adjunct to diet and exercise in type 2 diabetes: helps achieve target HbA1c levels. - Monotherapy in newly diagnosed type 2 diabetes: provides effective blood glucose reduction.

Gliclazide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially with missed meals. - Weight gain: modest increase in body weight. - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged low glucose requiring medical intervention. - Allergic reactions: rash, pruritus, or angioedema. - Hematologic disorders: agranulocytosis or aplastic anemia. - Hepatic dysfunction: jaundice or elevated liver enzymes.

When prescribing gliclazide, several safety considerations should be observed. - Blood glucose monitoring: regularly check levels to avoid hypoglycemia. - Renal impairment: dose may need adjustment in reduced kidney function. - Hepatic disease: use cautiously in patients with liver dysfunction. - Sulfonylurea allergy: avoid in individuals with known hypersensitivity. - Pregnancy and lactation: category B; discuss risks with healthcare provider. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Gliclazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other sulfonylureas or meglitinides: additive hypoglycemic effect. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase gliclazide plasma levels. - MAO inhibitors: risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazide diuretics: can enhance hypoglycemic response. - NSAIDs: may potentiate blood‑glucose lowering. - Alcohol: can potentiate hypoglycemia, especially with fasting.